NeuroBo Pharmaceuticals logo
NeuroBo Pharmaceuticals NRBO

Annual report 2025
added 03-26-2026

report update icon

NeuroBo Pharmaceuticals Financial Statements 2011-2026 | NRBO

Annual Financial Statements NeuroBo Pharmaceuticals

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

- - 20.7 M 212 K 802 K 84.1 M 44.5 M 13.7 M 106 M 60.2 M - - - - -

Shares

1.77 M 705 K 5.07 M 322 K 771 K 16.4 M 5.22 M 552 K 414 K 232 K - - - - -

Historical Prices

- - 4.09 0.66 1.04 5.12 9.1 26.8 246 275 - - - - -

Net Income

-13 M -27.6 M -12.5 M -14 M -15.3 M -29.7 M -21.3 M -23.6 M -33.4 M -14.6 M -9.03 M -320 K - - -

Operating Income

-13.7 M -28.8 M -15.9 M -19.6 M -15.3 M -29.7 M -20.2 M -15.5 M -33.1 M -14.7 M -8.08 M -266 K - - -

Interest Expense

735 K 1.22 M 3.42 M 5.66 M 14 K -1 K -22 K -3 K -5 K -4 K 7 K 1 K - - -

EBITDA

-13.7 M -28.8 M -15.9 M -19.6 M -15.2 M -29.7 M -20.2 M -22.8 M -33.1 M -14.7 M -6.07 M -267 K - - -

Operating Expenses

13.7 M 28.8 M - - - 29.7 M 20.2 M 22.8 M 33.1 M 14.7 M - - - - -

General and Administrative Expenses

6.91 M 7.26 M 6.73 M 8.64 M 8.75 M 7.85 M 2.7 M 8.49 M - 5.96 M 3.18 M 214 K - - -

All numbers in USD currency

Quarterly Income Statement NeuroBo Pharmaceuticals

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

24.4 M 15.3 M 10.3 M 8.64 M 10.2 M 5.43 M 5.09 M 4.91 M 5.08 M 5.06 M 40.5 M 25.4 M 889 K 889 K 889 K 889 K 743 K 22 M 21.6 M 19.7 M 16.4 M 16.3 M 15.7 M 15.6 M 5.17 M 5.17 M 5.17 M 5.17 M 14.3 M 14.2 M 12.4 M 10.6 M 10.6 M 10.6 M 9.52 M 9.27 M 6.98 M 3.63 M 3.47 M 3.76 M 2.73 M 2.95 M - - - - - - - - - - - - - - - - -

Net Income

-3.38 M -4 M -3.67 M - -5.65 M -10.1 M -6.71 M - -3.82 M -734 K -2.6 M - -3.11 M -3.3 M -2.88 M - -3.46 M -3.92 M -3.32 M - -3.05 M -2.38 M -4.73 M - -3.62 M -1.9 M -2.46 M -3.66 M -6.08 M -6.68 M -7.22 M -6.75 M -8.67 M -10.5 M -7.5 M -7.21 M -3.88 M -1.39 M -2.1 M -2.57 M -2.57 M -1.61 M -2.28 M -196 K - - - - - - - - - - - - - - -

Operating Income

-3.48 M -4.3 M -3.89 M - -6.26 M -10.1 M -6.88 M - -3.89 M -3.81 M -2.52 M - -3.1 M -3.22 M -2.88 M - -3.46 M -3.93 M -3.33 M - -3.06 M -2.39 M -4.75 M - -3.64 M -1.89 M -2.45 M -3.3 M -5.91 M -6.53 M -7.06 M -6.57 M -8.54 M -10.5 M -7.5 M -7.23 M -3.4 M -1.84 M -2.23 M -2.51 M -2.37 M -1.61 M -1.59 M - - - - - - - - - - - - - - - -

Interest Expense

98 K 306 K 215 K - 607 K 31 K 167 K - 75 K 3.07 M - - - - - - 3 K 5 K 6 K - -1 K -1 K -1 K - -1.12 M -581 K -171 K -177 K -1 K -144 K -160 K -179 K -5 K -5 K -5 K 1 K -1 K -4 K -4 K 2 K 6 K -1 K -690 K - - - - - - - - - - - - - - - -

EBITDA

-3.47 M -4.3 M -3.88 M - -6.25 M -10.1 M -6.88 M - -3.89 M - -2.52 M - -3.08 M -3.2 M -2.86 M - -3.43 M -3.9 M -3.32 M - -3.05 M -2.38 M -4.74 M - -3.64 M -1.89 M -2.45 M -3.3 M -5.91 M -6.53 M -7.06 M -6.57 M -8.54 M -10.5 M -7.5 M -7.23 M -3.4 M -1.84 M -2.23 M -2.51 M -2.37 M -1.61 M -1.59 M - - - - - - - - - - - - - - - -

Operating Expenses

3.48 M 4.3 M - - 6.26 M 10.1 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1.84 M - - - 1.61 M - - - - - - - - - - - - - - - - -

General and Administrative Expenses

1.56 M 1.98 M 1.56 M - 1.74 M 2.01 M 1.98 M - 1.6 M 1.44 M 1.88 M - 2.53 M 2.24 M 1.96 M - 2.07 M 1.91 M 2.19 M - 1.8 M 1.72 M 2.6 M - 2.5 M 939 K 651 K 1.47 M 2.36 M 2.57 M 2.09 M 1.49 M 2.05 M 4.68 M 2.22 M 2.39 M 1.47 M 1.05 M 1.05 M 1.05 M 997 K 658 K 475 K - - - - - - - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements NeuroBo Pharmaceuticals NRBO
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting NeuroBo Pharmaceuticals plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Amgen Amgen
AMGN
$ 340.0 -0.75 % $ 183 B usaUSA
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
$ 12.32 -0.24 % $ 3.86 B usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 23.27 -1.63 % $ 2.96 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.36 -2.16 % $ 362 M britainBritain
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.76 4.35 % $ 9.05 B australiaAustralia
CymaBay Therapeutics CymaBay Therapeutics
CBAY
- - $ 3.45 B usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 2.57 -3.38 % $ 16.1 M usaUSA
Avid Bioservices Avid Bioservices
CDMO
- - $ 789 M usaUSA
Cidara Therapeutics Cidara Therapeutics
CDTX
- - $ 1.41 B usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
- - $ 169 M usaUSA
Cellectar Biosciences Cellectar Biosciences
CLRB
$ 2.75 1.48 % $ 7.17 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
- - $ 401 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
CTI BioPharma Corp. CTI BioPharma Corp.
CTIC
- - $ 1.2 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Cyclerion Therapeutics Cyclerion Therapeutics
CYCN
$ 3.48 -16.14 % $ 8.76 M usaUSA
Deciphera Pharmaceuticals Deciphera Pharmaceuticals
DCPH
- - $ 2.18 B usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
- - $ 2.02 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Dyadic International Dyadic International
DYAI
$ 0.88 1.66 % $ 31.8 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 89.62 -1.82 % $ 27.2 B germanyGermany
Coherus BioSciences Coherus BioSciences
CHRS
$ 1.67 - $ 196 M usaUSA
Akari Therapeutics, Plc Akari Therapeutics, Plc
AKTX
$ 3.8 7.34 % $ 256 B britainBritain
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA